Relief Therapeutics Holding AG/ CH1251125998 /
| 15/11/2024 11:14:37 | Chg. -0.44 | Volume | Bid17:19:55 | Ask17:19:51 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 6.22CHF | -6.61% | 392 Turnover: 2,464.34 |
-Bid Size: - | -Ask Size: - | 85.65 mill.CHF | - | - |
GlobeNewswire
20/12/2023
Tonix Pharmaceuticals Announces Highly Statistically Significant and Clinically Meaningful Topline R...
GlobeNewswire
07/03/2022
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilit...
GlobeNewswire
02/03/2022
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
GlobeNewswire
27/01/2022
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upco...
GlobeNewswire
19/11/2021
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
GlobeNewswire
26/10/2021
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-...
GlobeNewswire
07/10/2021
Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Form...
GlobeNewswire
06/10/2021
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Filing of New Drug Application...
GlobeNewswire
09/08/2021
Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. ...
GlobeNewswire
25/05/2021
Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021 Following Pre-NDA Meeting with FDA
GlobeNewswire
17/05/2021
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update
GlobeNewswire
22/03/2021
Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and ...
GlobeNewswire
01/03/2021
Acer Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate...
GlobeNewswire
25/01/2021
Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Colla...
GlobeNewswire
16/07/2020
NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2...
GlobeNewswire
24/06/2020
NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Avipt...
GlobeNewswire
11/06/2020
Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 ...
GlobeNewswire
08/06/2020
Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID...
GlobeNewswire
01/06/2020
Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Cli...
